[1] Pinato DJ,Howell J,Ramaswami R,et al.Review article: delivering precision oncology in intermediate-stage liver cancer.Aliment Pharmacol Ther,2017,45(12):1514-1523. [2] Li J,Zhang F,Yang J,et al.Combination of individualized local control and target-specific agent to improve unresectable liver cancer managements:a matched case-control study.Target Oncol,2015,10(2):287-295. [3] 周晓琳. TACE术治疗原发性肝癌患者临床路径分析. 实用肝脏病杂志,2012,15(6):580-581. [4] Edeline J,Boucher E,Rolland Y,et al.Comparison of tumor response by response evaluation criteria in solid tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer,2017,118(1):147-156. [5] Jiang T,Zhu AX,Sahani DV.Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. J Hepatol,2013,58(1):169-177. [6] Jia Z,Diao XH,Jin JM,et al.Superb microvascular imaging—A new vascular detecting ultrasonographic technique for avascular breast masses:A preliminary study. Eur J Radiol,2016,85(5):915-921. [7] Hans P.American association for the study of liver diseases. Hepatology,2010,18(7):1-5. [8] Yamada T,Makita F,Takehara K,et al.Evaluation of the therapeutic effect of TAE on primary liver cancer. Cancer Chemother Pharmacol,1994,33(1):55-59. [9] Huppert P,Wenzel T,Wietholtz H. transcatheter arterial chem-oembolization(TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage patient population. Cardiovasc Intervent Radiol,2014,37(1):154-164. [10] Au J,Frenette C.Development of tivantinib as treatment for hepatocellular carcinoma. J Clin Transl Hepatol,2013,1(1):75-78. [11] Patidar KR,Kang L,Siddiqui MS,et al.The utility of fractional excretion of urea for the differential diagnosis of acute kidney injury in decompensated cirrhotics on diuretic therapy. Gastroenterology,2017,152(5):1149. [12] Minami Y,Kudo M.Therapeutic response assessment of transcatheter arterial chemoembolization for hepatocellular carcinoma:ultrasonography,CT and MR imaging. Oncology,2013,84(1):58-63. [13] Wang Y,Liao J,Qi W,et al.Predictive value of conventional ultrasound and contrast-enhanced ultrasound in early recurrence of hepatocellular carcinoma after surgical resection. Ultrasound Med Biol,2016,42(5):1042-1048. [14] Tai CJ,Huang MT,Wu CH,et al.Contrast-enhanced ultrasound and computed tomography assessment of hepatocellular carcinoma after transcatheter arterial chemo-embolization:A systematic review. J Gastrointestin Liver Dis,2017,25(4):499-507. [15] Ma S,Liu J,Zhang Y,et al.Application of color Doppler ultrasound combined with Doppler imaging artifacts in the diagnosis and estimate of congenital hypertrophic pyloric stenosis. Sci Rep,2017,7(1):9527. [16] Lecler A,Boucenna M,Lafitte F,et al.Usefulness of colour Doppler flow imaging in the management of lacrimal gland lesions. Eur Radiol,2016,27(2):1-11. [17] 罗福成. 原发性肝癌血供的彩色多普勒超声检查研究进展. 实用肝脏病杂志,2005,8(6):372-375. [18] 刘水清,马一博,韩宗宏, 等. 超微细血流成像技术评价原发性肝癌介入治疗疗效的价值. 中华肝脏病杂志,2017,25(7):328-331. [19] Cantisani V,David E,Ferrari D,et al.Color Doppler ultrasound with superb microvascular imaging compared to contrast-enhanced ultrasound and computed tomography angiography to identify and classify endoleaks in patients undergoing EVAR. Ann Vasc Surg,2017,40:136-145. [20] Sato T,Terasawa Y,Mitsumura H,et al.Utility of superb micro-vascular imaging(SMI) for evaluating morphological change after carotid artery stenting. Neurosonology,2017,30(2): 35-37. |